Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 15

Results For "MOMENTUM"

191 News Found

Launches and margin sustainability hold key for Glenmark: ICICI Direct
News | February 15, 2022

Launches and margin sustainability hold key for Glenmark: ICICI Direct

Key takeaways of Q3FY22 quarter & conference call highlights


OPPI-QCI announce awards to celebrate excellence in manufacturing facility 2021
News | February 11, 2022

OPPI-QCI announce awards to celebrate excellence in manufacturing facility 2021

The awards will be conferred to the winners at the annual summit of OPPI, scheduled on March 23-24


Venus Remedies join AMR alliance to combat global health threat
Biotech | February 07, 2022

Venus Remedies join AMR alliance to combat global health threat

The antimicrobial resistance alliance recently released its third Progress Report, reflecting on collective achievements from the life sciences industry


Sun Pharma demonstrates strong performance on all fronts: ICICI Direct
News | February 04, 2022

Sun Pharma demonstrates strong performance on all fronts: ICICI Direct

Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses


Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct
News | January 31, 2022

Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct

ICICI Direct analysis of Dr Reddy’s Q3FY22 results


Cipla has strong traction in India and the US: ICICI Direct
News | January 31, 2022

Cipla has strong traction in India and the US: ICICI Direct

ICICI Direct’s analysis of Cipla’s Q3FY22 results


Sun Pharma Q3FY22 PAT at Rs 2058.8 cr.
News | January 31, 2022

Sun Pharma Q3FY22 PAT at Rs 2058.8 cr.

Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021


ARVs bottom out while CRAMS growth continues for Laurus Labs: ICICI Direct
News | January 29, 2022

ARVs bottom out while CRAMS growth continues for Laurus Labs: ICICI Direct

The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct


Cipla’s Q3FY22 PAT at Rs 729 cr.
News | January 26, 2022

Cipla’s Q3FY22 PAT at Rs 729 cr.

Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.


Australia grants provisional registration for Novavax Covid-19 vaccine
Drug Approval | January 20, 2022

Australia grants provisional registration for Novavax Covid-19 vaccine

Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia